中文摘要：

目的：探讨HBV基因型和阿德福韦酯疗效之间的关系。方法：选取应用阿德福韦酯10mg/d进行抗病毒治疗48周的37例慢性乙型肝炎患者作为研究对象。从患者血清中提取HBV DNA,然后扩增S基因片段,对S基因测序后与已知各HBV基因型S基因序列用生物软件进行同源性比较后构建系统发生树,分析基因型。在对阿德福韦酯疗效进行评价的基础上,分析HBV基因型和阿德福韦酯疗效间的关系。结果：37份样本中有23份属于HBV基因型B,有14份属于HBV基因型C。阿德福韦酯治疗48周时,HBV DNA有效抑制（较基线下降2log10以上）率和转阴（低于检测下限）率在基因型B分别为60.9%（14/23）和43.5%（10/23）,在基因型C分别为71.4%（10/14）和42.9%（6/14）,差异均无显著性（P分别为0.724、1.000）;基因型B、C的ALT复常率分别为60.9%（14/23）和71.4%（10/14）,差异无显著性（P=0.724）;基因型B、C的HBeAg转阴率分别为31.8%（7/22）、38.5%（5/13）,差异无显著性（P=0.726）;基因型B、C的HBeAg血清转换率分别为9.1%（2/22）、23.1%（3/13）,差异无显著性（P=0.337）。结论：本研究所观察的样本中,HBV基因B型和C型与阿德福韦酯的抗病毒疗效可能无关。由于本研究纳入的样本量相对较少,尚需扩大样本进行进一步的研究。

英文摘要：

Objective：To study the relationship between the HBV genotypes and the efficacy of adefovir dipvoxil in treating patients with chronic hepatitis B.Methods：Thirty-seven patients with chronic hepatitis B,who were treated by adefovir dipivoxil 10mg per day for 48 weeks,were selected by expectation.To extract the HBV DNA from the patients blood serum.The surface genes of hepatitis B viruses were amplified by the polymerase chain reaction and sequenced.The relationship of these new S gene sequences to those of the published previously was investigated by constructing a phylogenetic tree,which classified these new S gene sequences into different groups,so it could determine the HBV genotypes.Results：Thirty-seven cases were studied,23 cases were HBV genotype B and 14 cases were HBV genotype C.At the week 48,a decline of at least 2 log10 from baseline HBV DNA was 60.9%（14/23） and 71.4%（10/14） in HBV genotype B and C,the difference is not significant.HBV DNA below the detection limit of 103 copies/ml was 43.5%（10/23）and 42.9%（6/14）in HBV genotype B and C,the difference is not significant.Normalization of ALT levels was 60.9%（14/23）and 71.4%（10/14）in HBV genotype B and C,the difference is not significant.HBeAg nagative and HBeAg seroconversion were 31.8%（7/22）and 9.1%（2/22）in genotype B,38.5%（5/13）and 23.1%（3/13）in genotype C,the difference is not significant.Conclusion：There is no conspicuous association between HBV genotype B,C and the efficancy of adefovir dipivoxil in treating patients with chronic hepatitis B.